199 related articles for article (PubMed ID: 17090671)
1. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
2. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice.
Yang R; Tang Q; Miao F; An Y; Li M; Han Y; Wang X; Wang J; Liu P; Chen R
Int J Nanomedicine; 2015; 10():7345-58. PubMed ID: 26677324
[TBL] [Abstract][Full Text] [Related]
4. Expression of heat shock protein 90 at the cell surface in human neuroblastoma cells.
Cid C; Regidor I; Poveda PD; Alcazar A
Cell Stress Chaperones; 2009 May; 14(3):321-7. PubMed ID: 18800240
[TBL] [Abstract][Full Text] [Related]
5. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.
Samuni Y; Ishii H; Hyodo F; Samuni U; Krishna MC; Goldstein S; Mitchell JB
Free Radic Biol Med; 2010 Jun; 48(11):1559-63. PubMed ID: 20211249
[TBL] [Abstract][Full Text] [Related]
7. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells.
Wang Y; Chen Q; Wu D; Chen Q; Gong G; He L; Wu X
Cell Death Dis; 2021 Aug; 12(8):786. PubMed ID: 34381017
[TBL] [Abstract][Full Text] [Related]
8. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
Kitson RR; Moody CJ
Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
[TBL] [Abstract][Full Text] [Related]
9. HSP90 Inhibition Attenuated Isoflurane-Induced Neurotoxicity in Mice and Human Neuroglioma Cells.
Zhang C; Chen X; Liu R; Zhao G
Neurochem Res; 2024 Mar; 49(3):706-717. PubMed ID: 38055149
[TBL] [Abstract][Full Text] [Related]
10. Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum.
Meyer KJ; Caton E; Shapiro TA
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866861
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and In Vitro Investigation of Novel Basic Celastrol Carboxamides as Bio-Inspired Leishmanicidal Agents Endowed with Inhibitory Activity against
Bassanini I; Parapini S; Ferrandi EE; Gabriele E; Basilico N; Taramelli D; Sparatore A
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33466300
[TBL] [Abstract][Full Text] [Related]
12. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2021 Jan; 42(1):132-141. PubMed ID: 32404982
[TBL] [Abstract][Full Text] [Related]
13. Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach.
Xu M; Zhao C; Zhu B; Wang L; Zhou H; Yan D; Gu Q; Xu J
J Med Chem; 2021 Feb; 64(4):2010-2023. PubMed ID: 33543615
[TBL] [Abstract][Full Text] [Related]
14. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Hu ZY; Lu J; Zhao Y
Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and preliminary evaluation steroidal antiestrogen-geldanamycin conjugates.
Adam Hendricks J; Hanson RN; Amolins M; Mihelcic JM; Blagg BS
Bioorg Med Chem Lett; 2013 Jun; 23(12):3635-9. PubMed ID: 23648180
[TBL] [Abstract][Full Text] [Related]
16. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
[TBL] [Abstract][Full Text] [Related]
17. Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin.
Ponta A; Akter S; Bae Y
Pharmaceuticals (Basel); 2011 Sep; 4(10):1281-1292. PubMed ID: 27721325
[TBL] [Abstract][Full Text] [Related]
18. Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention.
Bylicky MA; Shankavaram U; Aryankalayil MJ; Chopra S; Naz S; Sowers AL; Choudhuri R; Calvert V; Petricoin EF; Eke I; Mitchell JB; Coleman CN
Mol Cancer Ther; 2024 Apr; 23(4):577-588. PubMed ID: 38359816
[TBL] [Abstract][Full Text] [Related]
19. Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
Cancer Chemother Pharmacol; 2018 Nov; 82(5):911-912. PubMed ID: 30173339
[TBL] [Abstract][Full Text] [Related]
20. Author Correction: DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2024 Mar; 45(3):660. PubMed ID: 38012293
[No Abstract] [Full Text] [Related]
[Next] [New Search]
